Lumasiran
Modify Date: 2024-01-03 13:23:18
Lumasiran structure
|
Common Name | Lumasiran | ||
|---|---|---|---|---|
| CAS Number | 1834610-13-7 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LumasiranLumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1)[1][2]. |
| Name | Lumasiran |
|---|
| Description | Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1)[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Lumasiran reduced urinary oxalate excretion, the cause of progressive kidney failure in PH1[1]. |
| In Vivo | Lumasiran sodium is a subcutaneously administered, liver-directed RNA interference (RNAi) therapeutic agent[2]. |
| References |
[1]. Scott LJ, et al. Lumasiran: First Approval. Drugs. 2021;81(2):277-282. |
| No Any Chemical & Physical Properties |